IP Library › Granted Patent US 12,459,990
Granted Patent B2
US 12,459,990 · App. 17/625,247 · Granted Nov 4, 2025

Anti-HIV vaccine antibodies with reduced polyreactivity

Inventors: Stuart A. Sievers (Encino, CA); Jennifer Keeffe (Pasadena, CA); Michel C. Nussenzweig (New York, NY); Pamela J. Bjorkman (La Canada, CA)
Assignees: California Institute of Technology; The Rockefeller University
C07K16/1045A61K39/42A61K45/06A61P31/18C07K2317/31C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,459,990
App. No.
17/625,247
Granted
Nov 4, 2025
Kind
B2
Abstract

This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g., reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.

Claims (14)

1 . An isolated anti-HIV antibody, or antigen-binding portion thereof, comprising a set of heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) contained in SEQ ID NO: 4 and a set of light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) contained in SEQ ID NO: 36.

2 . An isolated anti-HIV antibody, or antigen-binding portion thereof, comprising a set of heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) comprising the respective sequences of SEQ ID NOs: 81, 110, and 87, and a set of light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) comprising the respective sequences of SEQ ID NOs: 100, 93, and 96.

3 . The isolated anti-HIV antibody, or antigen-binding portion thereof of claim 2 , comprising a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO: 111 and a light chain variable region that comprises the amino acid sequence of SEQ ID NO: 112.

4 . The isolated anti-HIV antibody, or antigen-binding portion thereof of claim 3 , comprising

a heavy chain having the heavy chain amino acid sequence of SEQ ID NO: 4 and a light chain having the light chain amino acid sequence of SEQ ID NO: 36.

5 . The isolated anti-HIV antibody, or antigen-binding portion thereof, of claim 4 , wherein the isolated anti-HIV antibody is a bispecific antibody comprising a first antigen binding arm binding to a first antigen and a second antigen binding arm binding to a second antigen, wherein the first antigen and the second antigen are different, and wherein the first antigen binding arm comprising the heavy chain amino acid sequence and the light chain amino acid sequence as set forth in claim 1 .

6 . The isolated anti-HIV antibody, or antigen-binding portion thereof, of claim 5 , wherein the second antigen is selected from the group consisting of CD3, FcγRI (CD64), FcγRII (CD32), FcγRIII (CD 16); CD89, CCR5, CD4, CD8, CD28, CD137, CTLA-4, gp41, killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3), killer cell lectin like receptor C1 (KLRC1), killer cell lectin like receptor C2 (KLRC2), killer cell lectin like receptor C3 (KLRC3), killer cell lectin like receptor C4 (KLRC4), killer cell lectin like receptor D1 (KLRD1), killer cell lectin like receptor K1 (KLRK1), natural cytotoxicity triggering receptor 3 (NCR3 or NKp30), natural cytotoxicity triggering receptor 2 (NCR2 or NK-p44), natural cytotoxicity triggering receptor 1 (NCR1 or NK-p46), CD226 (DNAM-1), cytotoxic and regulatory T cell molecule (CRTAM or CD355), signaling lymphocytic activation molecule family member 1 (SLAMF1), CD48 (SLAMF2), lymphocyte antigen 9 (LY9 or SLAMF3), CD244 (2B4 or SLAMF4), CD84 (SLAMF5), SLAM family member 6 (SLAMF6 or NTB-A), SLAM family member 7 (SLAMF7 or CRACC), CD27 (TNFRSF7), semaphorin 4D (SEMA4D or CD 100), and CD 160 (NK1), and a second epitope of gp120.

7 . A pharmaceutical composition comprising (i) the anti-HIV antibody of claim 4 and (ii) a pharmaceutically acceptable carrier.

8 . The pharmaceutical composition of claim 7 , further comprising a second therapeutic agent.

9 . The pharmaceutical composition of claim 8 , wherein the second therapeutic agent comprises an antiviral agent or one or more additional antibodies.

10 . The pharmaceutical composition of claim 9 , wherein the one or more additional antibodies comprises a second anti-HIV antibody or antigen binding portion thereof, or a third antibody binding to a third antigen.

11 . The pharmaceutical composition of claim 10 , wherein the third antigen is selected from the group consisting of CD3, FcγRI (CD64), FcγRII (CD32), FcγRIII (CD 16); CD89, CCR5, CD4, CD8, CD28, CD137, CTLA-4, gp41, killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2), killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3), killer cell lectin like receptor C1 (KLRC1), killer cell lectin like receptor C2 (KLRC2), killer cell lectin like receptor C3 (KLRC3), killer cell lectin like receptor C4 (KLRC4), killer cell lectin like receptor D1 (KLRD1), killer cell lectin like receptor K1 (KLRK1), natural cytotoxicity triggering receptor 3 (NCR3 or NKp30), natural cytotoxicity triggering receptor 2 (NCR2 or NK-p44), natural cytotoxicity triggering receptor 1 (NCR1 or NK-p46), CD226 (DNAM-1), cytotoxic and regulatory T cell molecule (CRTAM or CD355), signaling lymphocytic activation molecule family member 1 (SLAMF1), CD48 (SLAMF2), lymphocyte antigen 9 (LY9 or SLAMF3), CD244 (2B4 or SLAMF4), CD84 (SLAMF5), SLAM family member 6 (SLAMF6 or NTB-A), SLAM family member 7 (SLAMF7 or CRACC), CD27 (TNFRSF7), semaphorin 4D (SEMA4D or CD 100), and CD 160 (NK1), and a second epitope of gp120.

12 . The pharmaceutical composition of claim 9 , wherein the antiviral agent is selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an entry or fusion inhibitor, and an integrase inhibitor.

13 . A kit comprising a pharmaceutically acceptable dose unit of a pharmaceutically effective amount of the isolated anti-HIV antibody of claim 4 , or antigen-binding portion thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2022
From: NUSSENZWEIG, MICHEL C.
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 058915/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2022
From: SIEVERS, STUART A.; KEEFFE, JENNIFER; BJORKMAN, PAMELA J.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 058915/0503 →
Continuity (2)
Provisional Application 62871393 · Jul 8, 2019
Related Publication 20220289829A1 · Sep 15, 2022
References Cited (23)
US 10239935B2 · Balakrishnan et al. · 2019 [cited by applicant]
US 20180118816A1 · Keyt · 2018 [cited by examiner]
US 20200223907A1 · Balakrishnan · 2020 [cited by examiner]
WO 2013090644A2 · 2013 [cited by applicant]
WO 2016133927A1 · 2016 [cited by applicant]
WO 2016149695A1 · 2016 [cited by applicant]
WO 2016168758A1 · 2016 [cited by applicant]
WO 2018183294A1 · 2018 [cited by applicant]
WO 2014205491A1 · 2024 [cited by applicant]
Harmsen and Haard (Appl Microbiol Biotechnol 2007, 77:13-22). [cited by examiner]
Fera, et al. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci USA, Jul. 15, 2014, vol. 111, No. 28, pp. 10275-10280. [cited by applicant]
International Search Report and Written Opinion mailed Dec. 3, 2020 in related application No. PCT/US20/41138, 11 pages. [cited by applicant]
Huang, J. et al., “Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth”, Immunity (2016), vol. 45:5, pp. 1108-1121. [cited by applicant]
Diskin, Ron et al., “Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies”, J. Exp. Med (2013), vol. 210, pp. 1235-1249. [cited by applicant]
Diskin, Ron et al. “Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design”, Science (2011), vol. 334, pp. 1289-1293. [cited by applicant]
Ma, Jing et al., “Research Progress on Technology of HIV Antibody Detection”, Chinese Journal of Virology (2006), vol. 22, pp. 155-158 (machine English translation). [cited by applicant]
Rudikoff, S. et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, PNAS (1982), vol. 79, pp. 1979-1983. [cited by applicant]
Caskey, M. et al., “3BNC117 A Broadly Neutralizing Antibody Suppresses Viremia in HIV-1 Infected Humans”, Nature (2015), pp. 487-491. [cited by applicant]
Liu, M. et al., “Polyreactivity and Autoreactivity among HIV-1 Antibodies”, Journal of Virology (2015), vol. 89:1, pp. 784-798. [cited by applicant]
Hua, C. K. et al., “Engineering Broadly Neutralizing Antibodies for HIV Prevention and Therapy”, Advance Drug Delivery Reviews (2016), vol. 103, pp. 157-173. [cited by applicant]
Prigent, J. et al., “Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity”, Cell (2018), vol. 23:9, pp. 2568-2581. [cited by applicant]
Sievers, S. A. et al., “Antibody Enginerring for Increased Potency, Breadth and Half-Life”, Current Opinion in HIV and AIDS (2015), vol. 10:3, pp. 151-159. [cited by applicant]
Extended Search Report issued Oct. 20, 2023 in related European Patent Application No. 20836440.6, 19 pgs. [cited by applicant]